Contact: Jeff Ezell
BD Public Relations
(201) 847-5533
Email: jeff_ezell@bd.com

Franklin Lakes, N.J. (July 26, 2007) --

BD (Becton, Dickinson and Company) announced plans today to expand its distribution center in Temse, Belgium to meet increased demand for BD Biosciences and BD Diagnostics products throughout Western and Eastern Europe, the Middle East and Africa.

This expanded distribution center will be the result of a planned US$29 million investment in the project, which includes the purchase and renovation of previously leased space and the construction of a new state-of-the-art facility. The planned 55,000-square foot facility will be constructed adjacent to BD’s two existing distribution centers in the TTS Zone.

“This strategic investment in the Temse site will further enable BD’s Customer Driven Logistics service strategy that aims to effectively and efficiently serve our important European, African, and Middle Eastern customers,” said Jean-Marc Dageville, President, Western Europe. “This new state-of-the-art, fully automated distribution center will be essential to BD’s competitiveness in the global economy.”

“Upon completion, the Temse facility will play an increasingly important role in enhancing the operational effectiveness of the Company’s entire supply chain,” said Larry P. Smith, Vice President of Global Supply Chain. “It will allow BD to provide customers with high levels of service and reduced lead times – all of which ultimately benefit the patients and researchers who rely on our products.”

Construction is scheduled to begin this summer and is expected to be completed in October 2008. BD opened two distribution centers in Temse in the early 1990s. Those facilities currently employ approximately 200 people.

About BD

BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people’s health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 27,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.

This press release contains certain forward-looking statements (as defined under Federal securities laws) regarding BD’s performance, including future revenues, earnings per share and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; increases in energy costs and their effect on, among other things, the cost of producing BD’s products; fluctuations in costs and availability of raw materials and in BD’s ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BD’s filings with the Securities and Exchange Commission) and changes in healthcare or other governmental regulation; issuance of new or revised accounting standards, as well as other factors discussed in BD’s filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.